Akeagen LLC discovers and develops potent and highly differentiated human antibody therapeutics to improve the lives of patients with serious diseases. We focus our R&D on immune-oncology and autoimmune indications, an area with highly unmet needs. Our unique approach and portfolio are based on our leading proprietary Akeagen CaMouseTM and CanAbTM platform technologies to effectively generate innovative single domain and bi-specific antibodies with superior properties for drug development.